Citi lowered the firm’s price target on Boston Scientific (BSX) to $94 from $102 and keeps a Buy rating on the shares. The firm adjusted targets in the medical technology group post the Q4 reports. Sector fundamentals remain “healthy” despite the recent volatility, the analyst tells investors in a research note. Citi’s top picks are iRhythm and Medtronic.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BSX:
- IHI, IHE, ARKG: Specialty Healthcare ETFs Offer Portfolio Diversification to Investors
- Boston Scientific Targets Drug-Resistant Motor Epilepsy With New Deep Brain Stimulation Trial
- Boston Scientific (BSX): CHAMPION AF Trial Poised to Strengthen Watchman Evidence, Broaden Adoption, and Support Buy Rating
- Boston Scientific’s ENTRUST Registry Targets Real-World Edge in Carotid Stroke Prevention
- VHT, IYH, IXJ: Revive Your Portfolio with These Healthcare ETFs